Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.

This letter to the editor discusses a study that compared the effectiveness and safety of two chemotherapy regimens, R-DHAOx and R-DHAC, in patients with certain types of lymphoma. The study included 88 adult patients from four French centers and analyzed outcomes such as overall survival, progression-free survival, and relapse rates. The results showed that while there was no significant difference in overall survival and progression-free survival between the two regimens, R-DHAC was associated with a lower incidence of relapse and seemed more beneficial for long-term remission. The choice of regimen may depend on the toxicity profile and subsequent treatment options. [Extracted from the article]